IGV-001 extended median overall survival to 20.3 months, 6.3 months longer than placebo, in newly diagnosed glioblastoma patients. The phase 2b trial showed a favorable safety profile, consistent with ...
IGV-001 improved median overall survival to 20.3 months in newly diagnosed GBM patients, compared to 14.0 months with standard care. The therapy demonstrated a favorable safety profile, with no ...
Imvax has shrugged off the failure of its phase 2b brain cancer trial to hit its primary endpoint, reporting evidence of improved overall survival (OS) and making a beeline for the FDA. The study ...
– Study data suggests IGV-001 provides patients with a clinically meaningful improvement in overall survival (+6.3 months; +45%) compared to the current standard of care for ndGBM – – Company plans to ...
Background: IGV-001 is a type of cellular immunotherapy currently being investigated for treating glioblastoma (NCT04485949). It uses the patient’s tumor to elicit an autologous immune response.
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Expanded Tech-Software Sector ETF (Symbol: IGV) where we have ...
PHILADELPHIA--(BUSINESS WIRE)--Imvax, Inc., a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies, today announced the closing of a $29 million financing ...
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Expanded Tech-Software Sector ETF (Symbol: IGV) where we have ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback